AdAlta Limited (1AD.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.003 (-14.29%) as of
Key statistics
- Market cap
- 9.64M
- Forward P/E
- -0.10
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0030 – 0.0080
- Beta
- 0.14
- Revenue (TTM)
- 404.25k
- Profit margin
- 0.00%
- Volume
- 81.54k
About AdAlta Limited
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hawthorn East, VIC, Australia
- Employees
- 2
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.